Raloxifene was approved in 1997 by the FDA for the treatment of osteoporosis in postmenopausal women, and it is currently in clinical trials for the chemoprevention of breast cancer. Before widespread use as a chemopreventive agent in healthy women, the potential cytotoxic mechanisms of raloxifene should be investigated. In the current study, raloxifene was incubated with GSH and either rat or human liver microsomes, and the metabolites and GSH conjugates were characterized using liquid chromatography-tandem mass spectrometry. Raloxifene was converted to raloxifene diquinone methide GSH conjugates, raloxifene o-quinone GSH conjugates, and raloxifene catechols. For comparison, three raloxifene catechols were synthesized and characterized. In particular, 7-hydroxyraloxifene was found to oxidize to the 6,7-o-quinone. As compared with raloxifene diquinone methide, which has a half-life of less than 1 s in phosphate buffer, the half-life of raloxifene 6,7-o-quinone was much longer at t 1/2 ) 69 ( 2.5 min. The stability offered by raloxifene 6,7-o-quinone implies that it may be more toxic than raloxifene diquinone methide. Cytotoxicity studies in the human breast cancer cell lines S30 and MDA-MB-231 showed that 7-hydroxyraloxifene was more toxic than raloxifene in both cell lines. These results suggest that raloxifene could be metabolized to electrophilic and redox active quinoids, which have the potential to cause toxicity in vivo.
Introduction
Tamoxifen (Figure 1 ) is the prototypical SERM, 1 which has been extensively used for the treatment of hormonedependent breast cancer and more recently as a chemopreventive agent in women at risk of developing breast cancer. However, reports have shown that tamoxifen can lead to an increased endometrial cancer risk (1) (2) (3) (4) (5) (6) (7) (8) and induce the formation of DNA adducts (9) (10) (11) . One of the proposed bioactivation pathways leading to the toxicity of tamoxifen suggests that the generation of reactive intermediates such as the tamoxifen carbocation (12) (13) (14) , o-quinone (15, 16) , and quinone methide (17) (18) (19) could cause DNA damage directly through the formation of DNA adducts or indirectly through the generation of reactive oxygen species, which oxidize DNA.
Raloxifene (Evista) is a second generation SERM that has been approved by the Food and Drug Administration for the treatment and prevention of osteoporosis in postmenopausal women (Figure 1 ) (20) . Raloxifene also inhibits the development of mammary tumors in animal models (21, 22) and is currently in clinical trials for the chemoprevention of breast cancer (STAR trial; Study of Tamoxifen and Raloxifene) (23) . The development of additional SERMs is ongoing, and the knowledge of mechanisms of toxicity of existing drugs should lead to less toxic SERMs in the future.
In this study, we describe the formation of raloxifene diquinone methide, raloxifene catechols, and raloxifene o-quinones in incubations of raloxifene with rat liver microsomes. In addition to the three raloxifene mono-GSH conjugates, which have already been identified and described by Chen et al. (24) , we detected three hydroxylated raloxifenes including the raloxifene catechols 7-and 3′-OHRA; two di-GSH conjugates; and three mono-GSH conjugates of 7-and 3′-OHRA. Similar results were observed in incubations of raloxifene with human liver microsomes. Three raloxifene catechols were synthesized as standards and used for further study. Cytotoxicity studies in S30 (ERR-positive) and MDA-MB-231 (ERRnegative) cell lines indicated that 7-OHRA is a toxic addition. Compound 6 (1.5 g, 3.55 mmol) in 10 mL of dry DMF was added to this solution, and the mixture was stirred at room temperature for 15 min. The mixture was then poured into 100 mL of water and extracted with ethyl acetate (3 × 100 mL). The extracts were combined, dried over Na2SO4, and evaporated under reduced pressure. The mixture was subject to column chromatography with chloroform followed by methanol. The methanol was evaporated under reduced pressure to give 1.78 g (3.35 mmol, 94% yield) of product 7 as a yellow oil. 1 8 . A solution of 6 (1.5 g, 2.83 mmol) in 25 mL of dry CH2Cl2 under Ar was cooled to -78°C in a dry ice/acetone bath. To this was added AlCl3 (3.4 g, 25.4 mmol) followed by ethanethiol (1.68 mL, 22.6 mmol). The reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction was quenched by the addition of 16 mL of THF followed by 4 mL of 20% aqueous HCl and 16 mL of degassed water at a rate such that the temperature remained below 25°C
. The precipitate was recrystallized from degassed and nitrogen-purged methanol and water (1:1, v/v) to give 7-OHRA, 8 (1.1 g, 80%), as a yellow powder. The purity was estimated to be >97% by HPLC using method A. 1 20 . Compound 20 was synthesized using an analogous procedure to the synthesis of 4 except that the reaction was maintained at 60-65°C for 1 h, and then, the temperature was increased to 80-85°C for 1 h. The yield was 64%. 1 
[
6-Hydroxy-2-(3,4-dihydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride (3′-OHRA) 24.
The final product was crystallized from nitrogen-saturated methanol and water (1:1, v/v). The yield was 70%. The purity was estimated to be >80% using HPLC by method A. 1 Preparation of Raloxifene Diquinone Methide and 6,7-o-Quinone. Activated silver oxide (26) was prepared by adding KOH (0.72 g in 20 mL of H2O) to AgNO3 solution (2.0 g in 20 mL of H2O). The mixture was stirred for 15 min, and the precipitate was washed with water, filtered, and dried. Raloxifene diquinone methide was prepared by silver oxide oxidation. Briefly, raloxifene (5 mg) was dissolved in anhydrous acetonitrile (5 mL) and was preheated to 60°C. Activated silver oxide (500 mg) was added to this mixture and stirred for 10 s. The mixture was then filtered and either subjected to UV analysis or added to rapidly stirred GSH solution as described below. Raloxifene 6,7-o-quinone was prepared from 7-OHRA using a similar procedure except that the reaction mixture was stirred at room temperature for 15 min. UV (acetonitrile) 290, 390 nm. Elec-
Kinetic Studies of Raloxifene Diquinone Methide, 7-OHRA, and Raloxifene 6,7-o-Quinone. Freshly prepared raloxifene diquinone methide was added to phosphate buffer (pH 7.4) at 5°C. The decrease in the UV absorbance at 556 nm was monitored at a rate of 0.1 s/scan. Because the reaction was too fast to be monitored by this method, an accurate rate measurement was not obtained; however, the half-life of the raloxifene diquinone methide was estimated to be less than 1 s. The rate of formation of raloxifene 6,7-o-quinone was determined by adding 7-OHRA (25 µL, 2 mM in methanol) to phosphate buffer (975 µL, pH 7.4, 37°C). The increase in the UV absorbance at 390 nm was monitored at a rate of 2 s/scan. The reactivity of raloxifene 6,7-o-quinone was measured by adding freshly prepared 6,7-o-quinone (25 µL, 2 mM in acetonitrile) to phosphate buffer (975 µL, pH 7.4, 37°C). The decrease in the UV absorbance at 390 nm was monitored at a rate of 2 min/scan.
Reaction of Raloxifene Diquinone Methide and 6,7-oQuinone with GSH. A solution of raloxifene 6,7-o-quinone (2 mM) in acetonitrile (250 µL) was combined with GSH (0.5 mM) in phosphate buffer (10 mL, 50 mM, pH 7.4), and the mixture was stirred at room temperature for 5 min. Perchloric acid (0.5 mL) was added, and an aliquot (10 µL) of the mixture was analyzed using LC-MS-MS. The remaining solution was concentrated under reduced pressure and purified using semipreparative HPLC. A similar procedure was used for the reaction of raloxifene diquinone methide with GSH.
Cytotoxicity Studies in S30 and MDA-MB-231 Cells. The trypan blue exclusion assay was conducted to determine cell viability (27) . MDA-MB-231 cells were maintained in MEME supplemented with 5% fetal bovine serum (Atalanta Biologicals, Norcross, GA), 1% glutamax, 1% penicillin, streptomycin, fungizome, 1% nonessential amino acids, 6 µg/mL insulin (Sigma), and 5% CO2 at 37°C. The S30 cell line was maintained in the same medium as MDA-MB-231 cells supplemented with 5% 3× charcoal-dextran-treated fetal bovine serum and 500 µg/mL G418. All media products were purchased from Invitrogen (Carlsbad, CA) unless stated otherwise. The medium was routinely changed every 3 or 4 days, and it was changed 24 h prior to each experiment to maintain logarithmic growth. The cells were treated with test compound and assayed at 18 h. The test compounds were added in DMSO to give final concentrations from 5 to 100 µM. Negative controls (cells treated with DMSO only) were also carried out to define 100% cell viability. After treatment, floating cells were collected, attached cells were first trypsinized, and then floating and attached cells were combined. All cells were harvested by centrifugation at 2000 rpm for 5 min. Trypan blue stain (0.1 mL of 0.4%) was added to each cell suspension at a total volume of 0.6 mL. The cell suspension was transferred to a hemacytometer, and the number of cells was counted under a microscope. The dead cells were stained blue, and viable cells excluded the stain. The data represent the means ( SD of three determinations.
Results
Incubations of Raloxifene and Raloxifene Catechols with Liver Microsomes and GSH. We previously reported the detection of raloxifene metabolites in rat liver microsomes by using LC-MS-MS, which was consistent with raloxifene catechols and their o-quinone GSH conjugates (28) . Similarly, Chen et al. (24) found three mono-GSH conjugates of raloxifene in incubations of raloxifene with human liver microsomes. In the current study, we confirmed the metabolism of raloxifene to catechols and o-quinones by chemical synthesis of three of the potential raloxifene catechols: 7-OHRA, 3′-OHRA, and 5-OHRA (Scheme 1). These catechols were fully characterized by using both two-dimensional NMR including HMBC, COSY, HMQC, and mass spectrometry. Co-injections during LC-MS of these three raloxifene catechols with raloxifene incubated with microsomes indicated that both 7-OHRA and 3′-OHRA were formed whereas no 5-OHRA was detected. GSH conjugates formed in incubations of 7-OHRA with rat liver microsomes in the presence of GSH were identified as Incubation of 3′-OHRA with rat liver microsomes in the presence of GSH produced two mono-GSH conjugates with retention times of 23.1 and 25.7 min and one di-GSH conjugate with a retention time 14.2 min in the LC-MS chromatogram shown in Figure 2A , which were tentatively identified as 3′-OHRA-SG-1, 3′-OHRA-SG-2, and 3′-OHRA-diSG, respectively. During positive ion electrospray LC-MS, the mono-GSH conjugates produced protonated molecules of m/z 795, and the di-GSH conju-
2+ of m/z 551. The fragmentation patterns of these GSH conjugates ( Figure 3 ) were similar to those of 7-OHRA GSH conjugates. Comparison of these GSH conjugates with those formed in microsomal incubations of raloxifene showed that the two raloxifene catechol di-GSH conjugates that we reported previously (28) were 3′-OHRA-di-SG and 7-OHRA-di-SG, and the three raloxifene catechol mono-GSH conjugates were 3′-OHRA-SG-1, 7-OHRA-SG, and 3′-OHRA-SG-2.
The two major raloxifene catechol metabolites, 7-OHRA and 3′-OHRA, as well as one catechol mono-GSH conjugate, 7-OHRA-SG, were also detected in human liver microsomal incubations. In the human liver microsomal incubations of 7-OHRA and 3′-OHRA, the three catechol mono-GSH conjugates that we described previously were also detected. The catechol di-GSH conjugates were formed in minimal amounts or were not detected in the incubations of 3′-OHRA.
Kinetic Studies of Raloxifene Diquinone Methide, 7-OHRA, and Raloxifene 6,7-o-Quinone. Activated silver oxide is used to oxidize phenols and catechols to quinone methides and o-quinones, respectively (19) and was chosen in this study as the oxidant for the generation of raloxifene diquinone methide and 6,7-o-quinone. UV spectra of oxidized raloxifene in anhydrous acetonitrile showed absorbance maxima at 440 and 556 nm and that of raloxifene 6,7-o-quinone showed an absorbance maximum at 390 nm. Furthermore, the positive ion electrospray mass spectrum of raloxifene 6,7-o-quinone showed a protonated molecule of m/z 488. Because this ion was two mass units less than that of 7-OHRA, this provided additional evidence of o-quinone formation.
The addition of raloxifene diquinone methide to phosphate buffer at 37°C resulted in the immediate disappearance of the UV chromophore. Although the reaction was repeated at 5°C, it was still too fast to be monitored by conventional UV spectroscopy. As a result, an accurate reaction rate was not obtained; however, the half-life could be conservatively estimated to be less than 1 s at 5°C and would be expected to be much shorter under physiological conditions. In contrast to the raloxifene diquinone methide, the rate constant for the disappearance of raloxifene 6,7-o-quinone in phosphate buffer at 37°C was determined to be k obs ) 1. corresponding to a half-life of approximately 70 min. 7-OHRA was found to autoxidize to raloxifene 6,7-oquinone in phosphate buffer (pH 7.4, 37°C), and its autoxidation rate was calculated to be k obs ) 2.
, corresponding to a half-life of 4 min. Reaction of Raloxifene Diquinone Methide and 6,7-o-Quinone with GSH. The reaction of raloxifene diquinone methide with GSH produced three major products (data not shown), which were identical to the three raloxifene mono-GSH conjugates detected in the rat liver microsomal incubations. These conjugates appeared to be identical to those characterized by Chen et al. (24) in human liver microsomal incubations. The reaction of raloxifene 6,7-o-quinone with GSH produced one di-GSH conjugate, 7-OHRA-di-SG, and one mono-GSH conjugate, 7-OHRA-SG ( Figure 5 ). These two products were isolated using HPLC and analyzed using 1 H NMR. The partial NMR data and that of 7-OHRA are Table 1 . In the spectrum of 7-OHRA, the two doublet signals at 6.73 and 6.24 ppm were assigned to H-2′6′ and H-3′5′, and the two doublets at 7.24 and 6.52 ppm were assigned to H-2′′6′′ and H-3′′5′′. The two doublets, each integrating to one proton, at 6.30 and 6.46 ppm, were assigned to H-4 and H-5. In both GSH conjugates, H-2′6′, H-3′5′, H-2′′6′′, and H-3′′5′′ remained unaffected with the exception of a slight downfield shift; thus, all substitutions were determined to occur in the benzothiophene moiety. In 7-OHRA-di-SG, both H-4 and H-5 disappeared suggesting that GSH substitution had occurred at these positions giving 4,5-di-SG-7-OHRA. On the basis of NMR analysis, the identity of 7-OHRA-SG is suggested to be the 5-isomer, 5-SG-7-OHRA.
Cytotoxicity Studies in MDA-MB-231 and S30 Cells. Toxicities of raloxifene and its catechol metabolites, 7-OHRA and 3′-OHRA, in MDA-MB-231 and S30 cell lines are summarized in Table 2 . 7-OHRA was shown to be toxic in both cell lines and somewhat more toxic in S30 cells (IC 50 ) 24 µM) than in MDA-MB-231 cells (IC 50 ) 35 µM). Raloxifene was less toxic than 7-OHRA and did not show a significant difference between the two cell lines. Surprisingly, 3′-OHRA was not toxic in either cell line up to the solubility limit.
Discussion
Tamoxifen, an antiestrogen used in the treatment and prevention of breast cancer, is known to increase the risk of endometrial cancer, and the formation of quinoids has been postulated to play an important role (28) . The quinones and quinone methides formed from the metabolic activation of antiestrogens can cause damage in cells through alkylation of cellular macromolecules and through generation of reactive oxygen species (28) . Raloxifene is in clinical use for the treatment and prevention of osteoporosis in postmenopausal women, and it is currently in clinical trials for the chemoprevention of breast cancer. The current clinical use of raloxifene and, more importantly, the potential future long-term use in chemoprevention and treatment of postmenopausal symptoms raise concerns.
Raloxifene is a second generation SERM that retains similar structural motifs to 4-hydroxytamoxifen, the active metabolite of tamoxifen (20) . In particular, the polyaromatic phenolic core (Figure 1 ) of raloxifene should render this molecule redox reactive. We have shown that raloxifene autoxidizes in the presence of NO, and reaction with the biological oxidant peroxynitrite yields nitroaromatic and quinoid products that can form conjugates with GSH (30) . Most of the earlier pharmacokinetic studies on raloxifene suggested that it was primarily metabolized by glucuronidation and not by P450 oxidation (31) (32) (33) . However, a few published reports as well as the current study indicate otherwise (24, 34) . For example, mono-and dihydroxylated raloxifene metabolites were detected by using LC-MS-MS in incubations of raloxifene with rat liver microsomes (34) , although these metabolites were not characterized. GSH and N-acetylcysteine conjugates were identified (24) during raloxifene metabolic studies, which were possibly formed through the intermediacy of an electrophilic raloxifene diquinone methide (Figure 1 ). In addition, the drug was shown to be associated with decreases in P450 aromatase activities in human colon carcinoma cells (35) and importantly was shown to irreversibly inhibit P450 3A4 (24) . These data suggest that raloxifene might participate in similar toxic pathways to those proposed for tamoxifen.
In a recent study, raloxifene mono-GSH conjugates were identified during raloxifene metabolism (24) . In addition to these raloxifene mono-GSH conjugates, we provided a preliminary report of the formation of raloxifene catechols and catechol GSH conjugates (28) . Such evidence suggests that raloxifene might cause toxicity through the formation of both quinones and a diquinone methide. Chen et al. (24) proposed two possible mechanisms for the formation of raloxifene mono-GSH conjugates either through a raloxifene arene oxide intermediate or a raloxifene diquinone methide, followed by nucleophilic attack of GSH. In this study, we have successfully generated the raloxifene diquinone methide by chemical oxidation using silver oxide to study the mechanism of raloxifene GSH conjugate formation. When this diquinone methide was reacted with GSH, three GSH conjugates were obtained, which were identical to the raloxifene mono-GSH conjugates detected in microsomal incubations. These results provide strong support for the raloxifene diquinone methide pathway in the formation of raloxifene GSH conjugates. Kinetic studies showed that the raloxifene diquinone methide was highly reactive in phosphate buffer with a half-life of less than 1 s at 5°C
, which would be expected to be much shorter under physiological conditions. According to the relationship between toxicity and reactivity of quinone methides (36) , if a quinone methide is too reactive, it is less toxic due to its poor selectivity between nucleophilic cellular macromolecules and solvent or GSH. The high reactivity of the raloxifene diquinone methide makes it less likely to cause toxicity by alkylation of cellular macromolecules; therefore, this metabolite may not make a major contribution to the overall toxicity of raloxifene.
In addition to the three raloxifene mono-GSH conjugates, we detected three hydroxylated raloxifenes, as well as two di-GSH and three mono-GSH conjugates of hydroxylated raloxifenes. To identify these metabolites, three possible raloxifene catechols were synthesized as standards. Two of the three raloxifene catechols, 7-OHRA and 3-OHRA, are novel structures. Although 5-OHRA was first synthesized by Grese et al. (37) , we used a different synthetic procedure. The synthesis of differently substituted benzo[b]thiophene moieties was performed by the cyclization rearrangement induced by PPA, which has been described in the literature by Kost et al. (38) .
Using the three raloxifene catechols as standards, two of the three hydroxylated raloxifenes detected in the microsomal incubations were determined to be 7-OHRA and 3′-OHRA; however, no 5-OHRA was detected. The two catechols were then incubated with rat liver microsomes in the presence of GSH. Microsomal incubations of 7-OHRA gave one di-GSH conjugate, 7-OHRA-di-SG, and one mono-GSH conjugate corresponding to 7-OHRA-SG. Similar incubations with 3′-OHRA gave one di-GSH conjugate, 3′-OHRA-di-SG, and two mono-GSH conjugates, 3′-OHRA-SG-1 and 3′-OHRA-SG-2. These GSH conjugates were identical to those formed in the incubations of raloxifene with rat liver microsomes as determined by comparison with mass spectra and co-injection experiments with authentic standards. The raloxifene catechol GSH conjugates were probably formed through the initial formation of the raloxifene o-quinones followed by reaction with GSH. To demonstrate this proposed mechanism, 7-OHRA was used as an example and oxidized to raloxifene 6,7-o-quinone using silver oxide oxidation. Reaction of this o-quinone with GSH produced one di-GSH conjugate, 7-OHRA-di-SG, and one mono-GSH conjugate, 7-OHRA-SG. On the basis of the subsequent proton NMR analysis, they were determined to be 4,5-di-SG-7-OHRA and 5-SG-7-OHRA, respectively. The potential mechanism of the formation of the o-quinone GSH conjugates is shown in Scheme 2. After oxidation of raloxifene to 7-OHRA, the catechol could be further oxidized to raloxifene 6,7-o-quinone either by P450 or through autoxidation, followed by nucleophilic attack by GSH. Further oxidation of 5-SG-7-OHRA followed by the attack of another GSH molecule would yield 4,5-di-SG-7-OHRA. A similar mechanism can be proposed for 3′-OHRA.
Kinetic studies showed that the half-life of the raloxifene 6,7-o-quinone is 69 ( 2.5 min. As compared with the highly reactive diquinone methide, raloxifene 6,7-oquinone is relatively stable. The stability offered by this o-quinone implies that it may be more toxic than the raloxifene quinone methide. To investigate the relevance of the results obtained in rat liver microsomal incubations to humans, human liver microsomal incubations with raloxifene were also carried out (data not shown). In addition to the three raloxifene diquinone methide mono-GSH conjugates, the GSH conjugates of 7-OHRA and 3′-OHRA were also detected.
We examined the relative toxicity of raloxifene and its two major catechol metabolites, 7-OHRA and 3′-OHRA, in two breast cancer cell lines, S30 (ERR-positive) and MDA-MB-231 (ERR-negative). The MDA-MB-231 cell line is an ER-negative cell line, and the S30 cell line is an ER-positive cell line obtained from the MDA-MD-231 cell Scheme 2. Mechanism of the Formation of 7-OHRA GSH Conjugates line stably expressing ERR. We have previously shown that ERR positive cell lines are considerably more sensitive to the toxic effects of equine catechol estrogen metabolites (39) , and as a result, it was of interest to determine if similar effects were observed with raloxifene and its catechol metabolites. Our data showed that 7-OHRA was more toxic than raloxifene and that the S30 cells were more sensitive to the toxicity.
In summary, raloxifene was metabolized by both rat and human liver microsomes to electrophilic diquinone methide and o-quinones, which were trapped by GSH to form mono-and/or di-GSH conjugates. These electrophilic species have the potential to alkylate cellular macromolecules to cause toxicity. Among these electrophilic species, raloxifene diquinone methide seemed to be too reactive to be a major toxic metabolite while raloxifene 6,7-oquinone was relatively stable and could be the major alkylating species. These findings might be very important to evaluate the potential toxicity of raloxifene and might be useful guides for further investigations toward the safe long-term use of raloxifene.
